Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Surge in Drug-Affected Newborns Driven by Rural Opioid Use

By R&D Editors | December 13, 2016

A surge in U.S infants born with symptoms of withdrawal from heroin or strong prescription painkillers is driven largely by rising drug use among women in rural areas, a new study found.

The study, led by University of Michigan researchers, estimates that about 21 percent of newborns in rural counties had withdrawal symptoms in 2013, up from 13 percent in 2004.

Newborns whose mothers use these drugs during pregnancy are at risk for seizures, excessive crying, problems with breathing, sleeping and feeding and other withdrawal symptoms. Treatment sometimes includes methadone and babies may need to be hospitalized for weeks or months.

The study shows the rate for affected rural newborns climbed six-fold — from about 1 per 1,000 births in 2004 to almost 8 per 1,000 births in 2013. By contrast, in urban areas the rate climbed from 1 per 1,000 to 5 per 1,000 births. The rates correspond with women’s use of opioid drugs during pregnancy. This includes use or misuse of oxycodone and other prescription opioid painkillers, and use of illegal narcotics.

To come up with their estimate, the researchers analyzed a dataset of U.S. hospital discharges compiled by the government’s Agency for Healthcare Research and Quality. The results were published Monday in JAMA Pediatrics.

Earlier studies also found an increase nationwide, and other data show rural areas have been hard hit by the U.S. opioid epidemic.

The new study shows there’s an urgent need for more programs to make it easier for women in rural areas to obtain prevention services and treatment for addiction, the researchers said.

___

Online:

Newborn abstinence syndrome: http://tinyurl.com/j8ulul6

 

Related Articles Read More >

Two RFD4-Proteina-designed enzymes that break down the pesticide paraoxon, with their structural accuracy and catalytic efficiency.
NVIDIA and UW’s protein design model produces 158 binders from 188 designs
Schematic of a whole-brain Perturb-seq atlas split into 1,946 perturbation profiles, each analyzed by its own AI agent.
OpenAI deploys nearly 2,000 GPT-Rosalind agents to generate biological research leads in 32 minutes
Surgical team operating under overhead lights in a modern operating room
Why promising technologies stall on the path to market: Lessons from medtech
UK Sovereign AI grant helps fund immune profiling of 80,000 UK Biobank blood samples
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE